SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CIANCETTA, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.222
EU - Europa 2.785
AS - Asia 2.289
SA - Sud America 481
Continente sconosciuto - Info sul continente non disponibili 156
AF - Africa 66
OC - Oceania 7
Totale 10.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.120
FI - Finlandia 1.910
SG - Singapore 905
CN - Cina 458
BR - Brasile 376
IT - Italia 295
VN - Vietnam 283
HK - Hong Kong 227
DE - Germania 109
FR - Francia 87
GB - Regno Unito 85
BD - Bangladesh 80
RU - Federazione Russa 62
TR - Turchia 61
JP - Giappone 58
CA - Canada 57
UA - Ucraina 57
IN - India 56
PL - Polonia 56
AR - Argentina 39
SE - Svezia 36
MX - Messico 33
ID - Indonesia 28
ZA - Sudafrica 28
NL - Olanda 24
EC - Ecuador 22
IQ - Iraq 22
PH - Filippine 20
CO - Colombia 15
UZ - Uzbekistan 14
PK - Pakistan 13
AT - Austria 11
ES - Italia 11
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
CZ - Repubblica Ceca 8
MY - Malesia 8
LT - Lituania 7
BE - Belgio 6
KE - Kenya 6
PY - Paraguay 6
VE - Venezuela 6
AU - Australia 5
CL - Cile 5
KR - Corea 5
BO - Bolivia 4
CH - Svizzera 4
DZ - Algeria 4
EG - Egitto 4
JM - Giamaica 4
JO - Giordania 4
KZ - Kazakistan 4
MA - Marocco 4
PT - Portogallo 4
SA - Arabia Saudita 4
TW - Taiwan 4
UY - Uruguay 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
IL - Israele 3
PE - Perù 3
RS - Serbia 3
SY - Repubblica araba siriana 3
BY - Bielorussia 2
ET - Etiopia 2
GA - Gabon 2
IE - Irlanda 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
MN - Mongolia 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
CV - Capo Verde 1
CY - Cipro 1
EU - Europa 1
GF - Guiana Francese 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RO - Romania 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
UG - Uganda 1
Totale 9.851
Salva come PNG Salva come JPEG
Città #
Helsinki 1.886
Dallas 1.024
Ashburn 571
Singapore 508
San Jose 377
Santa Clara 229
Hong Kong 219
Beijing 190
Chandler 138
Fairfield 138
Ho Chi Minh City 103
Ferrara 102
Los Angeles 102
Houston 100
Ann Arbor 93
Woodbridge 85
New York 66
Hanoi 60
Council Bluffs 57
Tokyo 57
Jacksonville 56
Seattle 53
Warsaw 53
Wilmington 52
Cambridge 46
Lauterbourg 46
Princeton 46
Buffalo 39
São Paulo 35
Munich 33
Chicago 27
Izmir 25
Orem 24
Shanghai 24
Bologna 21
Chennai 21
Jakarta 21
London 19
San Diego 18
Toronto 18
Brooklyn 17
Nuremberg 17
Da Nang 16
Milan 16
Montreal 16
Johannesburg 15
Mexico City 15
Stockholm 14
Atlanta 13
Curitiba 13
Frankfurt am Main 13
Nanjing 13
Tashkent 13
Turku 13
Washington 13
Denver 12
Manchester 12
Phoenix 12
Baghdad 11
Boardman 11
Redondo Beach 11
Changsha 10
Poplar 10
San Francisco 10
Amsterdam 9
Falls Church 9
Quito 9
Boston 8
Brno 8
Irvine 8
Rio de Janeiro 8
The Dalles 8
Brasília 7
Buenos Aires 7
Can Tho 7
Haiphong 7
Hefei 7
Hải Dương 7
Belo Horizonte 6
Brussels 6
Dhaka 6
Lahore 6
Las Vegas 6
Manila 6
Rome 6
Salvador 6
Venice 6
Biên Hòa 5
Calgary 5
Charlotte 5
City of London 5
Guayaquil 5
Osasco 5
Padova 5
Redmond 5
Secaucus 5
Sumaré 5
Amman 4
Aryanah 4
Assago 4
Totale 7.323
Salva come PNG Salva come JPEG
Nome #
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 2.740
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 324
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 276
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 268
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 224
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 195
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 192
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 190
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 189
Design and synthesis of 1,4,8-triazaspiro[4.5]decan-2-one derivatives as novel mitochondrial permeability transition pore inhibitors 172
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 166
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 162
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 146
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 142
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study 140
A QM/MM study of the binding of RAPTA ligands to cathepsin B 140
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 137
null 118
Aquaporin inhibition by gold(III) compounds: New insights 114
Activation of carboplatin by carbonate: A theoretical investigation 111
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 110
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 108
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 108
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 108
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 106
Activation of carboplatin by chloride ions: a theoretical investigation 105
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 105
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 105
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 104
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 103
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 100
Advances in Computational Techniques to Study GPCR-Ligand Recognition 99
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 99
Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-: E] [1,2,4]triazolo[1,5- c] pyrimidin-5-amine functionalized congeners 96
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 96
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 95
Supramolecular delivery systems for polyphenols: A green approach to predict in vivo permeability through an in vitro setup 92
Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD) 91
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 91
null 90
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 90
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 88
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 86
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 84
Enhancing torsional sampling using fully adaptive simulated tempering 83
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 82
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 81
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 81
Journal of Medicinal Chemistry Collection: Drug Discovery in Italy 77
Implementing the “Best Template Searching” tool into Adenosiland platform 77
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 76
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 76
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 76
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 75
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 72
Exploring the recognition pathway at the human A2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations 72
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 70
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 64
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 62
Polypharmacology of conformationally locked methanocarba nucleosides 57
In silico 3D modeling of binding activities 57
Protein–Ligand Docking: Virtual Screening and Applications to Drug Discovery 52
P2Y14 Receptor 51
The path to the G protein-coupled receptor structural landscape: Major milestones and future directions 50
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 49
Inspecting receptor-ligand interaction using molecular dynamics simulations: new insights from Adenosiland 41
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 20
Totale 10.006
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.181
Totale 47.061
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022366 2 16 6 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/20251.244 19 21 98 23 137 100 38 64 229 172 183 160
2025/20266.889 394 383 1.139 452 621 203 508 237 2.212 454 174 112
2026/2027126 126 0 0 0 0 0 0 0 0 0 0 0
Totale 10.006